MET and cancer: Multiple point mutations were identified in the semaphoring, immunoglobulin plexin transcription, juxta-membrane (JM) or tyrosine kinase (TK) domains of MET, as Sattler and Reddy stated in their work.172 N375S mutation was identified in NSCLC, small cell lung cancer (SCLC), mesothelioma, and melanoma177–180; T992I in NSCLC, SCLC, mesothelioma and BCs and other mutations specifically identified in other cancer subtypes.181–184